Skip to content
10-Q

Quarterly Report

BRIACELL THERAPEUTICS CORP. BCTX BCTXL BCTXZ

0001493152-26-027928

← back to feed
Filed
Jun 9, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Jun 9, 2026 8.7M sh
Shares Diluted Q3 2026 · Apr 30, 2026 7.25M sh
Shares Diluted Q3 2026 · Apr 30, 2026 3.94M sh
Shares Diluted restated Q3 2026 · Apr 30, 2025 373.07K sh
Shares Diluted restated Q3 2026 · Apr 30, 2025 271.64K sh
Capex Q3 2026 · Apr 30, 2026 $127.05K
Operating Cash Flow Q3 2026 · Apr 30, 2026 −$22.69M
Operating Cash Flow Q3 2026 · Apr 30, 2025 −$20.04M
Short Term Investments Q3 2026 · Apr 30, 2026 $15.92M
Short Term Investments Q3 2026 · Jul 31, 2025 $7.37M
Cash And Equivalents Q3 2026 · Apr 30, 2026 $6.88M
Cash And Equivalents Q3 2026 · Jul 31, 2025 $10.49M
Current Liabilities Q3 2026 · Apr 30, 2026 $3.59M
Current Liabilities Q3 2026 · Jul 31, 2025 $3.98M
Current Assets Q3 2026 · Apr 30, 2026 $25.39M
Current Assets Q3 2026 · Jul 31, 2025 $19.93M
Total Assets Q3 2026 · Apr 30, 2026 $27.07M
Total Assets Q3 2026 · Jul 31, 2025 $21.65M
Eps Diluted Q3 2026 · Apr 30, 2026 −$0.99
Eps Diluted Q3 2026 · Apr 30, 2026 −$5.73
Eps Diluted restated Q3 2026 · Apr 30, 2025 −$16.42
Eps Diluted restated Q3 2026 · Apr 30, 2025 −$67.08
Eps Basic Q3 2026 · Apr 30, 2026 −$0.99
Eps Basic Q3 2026 · Apr 30, 2026 −$5.73
Eps Basic restated Q3 2026 · Apr 30, 2025 −$16.42
Eps Basic restated Q3 2026 · Apr 30, 2025 −$67.08
Sga Expense Q3 2026 · Apr 30, 2026 $1.65M
Sga Expense Q3 2026 · Apr 30, 2026 $4.77M
Sga Expense Q3 2026 · Apr 30, 2025 $1.52M
Sga Expense Q3 2026 · Apr 30, 2025 $4.49M
Rd Expense Q3 2026 · Apr 30, 2026 $5.97M
Rd Expense Q3 2026 · Apr 30, 2026 $18.7M
Rd Expense Q3 2026 · Apr 30, 2025 $4.81M
Rd Expense Q3 2026 · Apr 30, 2025 $14.16M
Net Income Q3 2026 · Apr 30, 2026 −$7.16M
Net Income Q3 2026 · Apr 30, 2026 −$22.58M
Net Income Q3 2026 · Apr 30, 2025 −$6.13M
Net Income Q3 2026 · Apr 30, 2025 −$18.22M
Operating Income Q3 2026 · Apr 30, 2026 −$7.62M
Operating Income Q3 2026 · Apr 30, 2026 −$23.48M
Operating Income Q3 2026 · Apr 30, 2025 −$6.33M
Operating Income Q3 2026 · Apr 30, 2025 −$18.65M